155 related articles for article (PubMed ID: 38058031)
21. Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey.
Passweg JR; Baldomero H; Chabannon C; Corbacioglu S; de la Cámara R; Dolstra H; Glass B; Greco R; Mohty M; Neven B; Peffault de Latour R; Perić Z; Snowden JA; Yakoub-Agha I; Sureda A; Kröger N;
Bone Marrow Transplant; 2022 May; 57(5):742-752. PubMed ID: 35194156
[TBL] [Abstract][Full Text] [Related]
22. Follow-up of patients with refractory or relapsed multiple myeloma after allogeneic hematopoietic cell transplantation.
Schneidawind C; Duerr-Stoerzer S; Faul C; Kanz L; Weisel K; Bethge W; Schneidawind D
Clin Transplant; 2017 Jul; 31(7):. PubMed ID: 28470884
[TBL] [Abstract][Full Text] [Related]
23. Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors.
Guru Murthy GS; Kim S; Hu ZH; Estrada-Merly N; Abid MB; Aljurf M; Bacher U; Badawy SM; Beitinjaneh A; Bredeson C; Cahn JY; Cerny J; Diaz Perez MA; Farhadfar N; Gale RP; Ganguly S; Gergis U; Hildebrandt GC; Grunwald MR; Hashmi S; Hossain NM; Kalaycio M; Kamble RT; Kharfan-Dabaja MA; Hamilton BK; Lazarus HM; Liesveld J; Litzow M; Marks DI; Murthy HS; Nathan S; Nazha A; Nishihori T; Patel SS; Pawarode A; Rizzieri D; Savani B; Seo S; Solh M; Ustun C; van der Poel M; Verdonck LF; Vij R; Wirk B; Oran B; Nakamura R; Scott B; Saber W
JAMA Oncol; 2022 Mar; 8(3):404-411. PubMed ID: 35024768
[TBL] [Abstract][Full Text] [Related]
24. Relapse of lymphoma after allogeneic hematopoietic cell transplantation: management strategies and outcome.
Wudhikarn K; Brunstein CG; Bachanova V; Burns LJ; Cao Q; Weisdorf DJ
Biol Blood Marrow Transplant; 2011 Oct; 17(10):1497-504. PubMed ID: 21338707
[TBL] [Abstract][Full Text] [Related]
25. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma.
Dhakal B; Shah N; Kansagra A; Kumar A; Lonial S; Garfall A; Cowan A; Poudyal BS; Costello C; Gay F; Cook G; Quach H; Einsele H; Schriber J; Hou J; Costa L; Aljurf M; Chaudhry M; Beksac M; Prince M; Mohty M; Janakiram M; Callander N; Biran N; Malhotra P; Otero PR; Moreau P; Abonour R; Iftikhar R; Silberman R; Mailankody S; Gregory T; Lin Y; Carpenter P; Hamadani M; Usmani S; Kumar S
Transplant Cell Ther; 2022 Jun; 28(6):284-293. PubMed ID: 35306217
[TBL] [Abstract][Full Text] [Related]
26. Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.
Tomblyn MR; Ewell M; Bredeson C; Kahl BS; Goodman SA; Horowitz MM; Vose JM; Negrin RS; Laport GG
Biol Blood Marrow Transplant; 2011 Jul; 17(7):1051-7. PubMed ID: 21073974
[TBL] [Abstract][Full Text] [Related]
27. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma.
Epperla N; Kumar A; Abutalib SA; Awan FT; Chen YB; Gopal AK; Holter-Chakrabarty J; Kekre N; Lee CJ; Lekakis L; Lin Y; Mei M; Nathan S; Nastoupil L; Oluwole O; Phillips AA; Reid E; Rezvani AR; Trotman J; Zurko J; Kharfan-Dabaja MA; Sauter CS; Perales MA; Locke FL; Carpenter PA; Hamadani M
Transplant Cell Ther; 2023 Sep; 29(9):548-555. PubMed ID: 37419325
[TBL] [Abstract][Full Text] [Related]
28. Chimeric Antigen Receptor T Cell Therapy versus Hematopoietic Stem Cell Transplantation: An Evolving Perspective.
Goldsmith SR; Ghobadi A; Dipersio JF; Hill B; Shadman M; Jain T
Transplant Cell Ther; 2022 Nov; 28(11):727-736. PubMed ID: 35878743
[TBL] [Abstract][Full Text] [Related]
29. Controversies in autologous and allogeneic hematopoietic cell transplantation in peripheral T/NK-cell lymphomas.
Shustov A
Best Pract Res Clin Haematol; 2013 Mar; 26(1):89-99. PubMed ID: 23768643
[TBL] [Abstract][Full Text] [Related]
30. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
31. Results of autologous and allogeneic hematopoietic cell transplant therapy for multiple myeloma.
Arora M; McGlave PB; Burns LJ; Miller JS; Barke JN; Defor TE; Weisdorf DJ
Bone Marrow Transplant; 2005 Jun; 35(12):1133-40. PubMed ID: 15834435
[TBL] [Abstract][Full Text] [Related]
32. Umbilical cord blood: an undervalued and underutilized resource in allogeneic hematopoietic stem cell transplant and novel cell therapy applications.
Shi PA; Luchsinger LL; Greally JM; Delaney CS
Curr Opin Hematol; 2022 Nov; 29(6):317-326. PubMed ID: 36066376
[TBL] [Abstract][Full Text] [Related]
33. Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia.
Zhao YL; Liu DY; Sun RJ; Zhang JP; Zhou JR; Wei ZJ; Xiong M; Cao XY; Lu Y; Yang JF; Zhang X; Lu DP; Lu P
Front Immunol; 2021; 12():605766. PubMed ID: 34025637
[TBL] [Abstract][Full Text] [Related]
34. Outcomes of hematopoietic cell transplantation for transformed follicular lymphoma.
Ida H; Inamoto Y; Fukuhara S; Maeshima AM; Takeda W; Hirakawa T; Kuno M; Aoki J; Tanaka T; Ito A; Kim SW; Izutsu K; Fukuda T
Hematol Oncol; 2021 Dec; 39(5):650-657. PubMed ID: 34431557
[TBL] [Abstract][Full Text] [Related]
35. Relapse of Hodgkin lymphoma after autologous transplantation: Time to rethink treatment?
Jethava Y; Guru Murthy GS; Hamadani M
Hematol Oncol Stem Cell Ther; 2017 Jun; 10(2):47-56. PubMed ID: 28183681
[TBL] [Abstract][Full Text] [Related]
36. Radioimmunotherapy in Combination with Reduced-Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Advanced Multiple Myeloma.
Fasslrinner F; Stölzel F; Kramer M; Teipel R; Brogsitter C; Morgner A; Arndt C; Bachmann M; Hänel M; Röllig C; Kotzerke J; Schetelig J; Bornhäuser M
Biol Blood Marrow Transplant; 2020 Apr; 26(4):691-697. PubMed ID: 31730919
[TBL] [Abstract][Full Text] [Related]
37. The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T's come into focus.
Passweg JR; Baldomero H; Chabannon C; Basak GW; Corbacioglu S; Duarte R; Dolstra H; Lankester AC; Mohty M; Montoto S; Peffault de Latour R; Snowden JA; Styczynski J; Yakoub-Agha I; Kröger N;
Bone Marrow Transplant; 2020 Aug; 55(8):1604-1613. PubMed ID: 32066864
[TBL] [Abstract][Full Text] [Related]
38. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
[TBL] [Abstract][Full Text] [Related]
39. Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma.
Maffini E; Storer BE; Sandmaier BM; Bruno B; Sahebi F; Shizuru JA; Chauncey TR; Hari P; Lange T; Pulsipher MA; McSweeney PA; Holmberg L; Becker PS; Green DJ; Mielcarek M; Maloney DG; Storb R
Haematologica; 2019 Feb; 104(2):380-391. PubMed ID: 30262560
[TBL] [Abstract][Full Text] [Related]
40. Prognostic factors of second hematopoietic allogeneic stem cell transplantation among hematological malignancy patients relapsed after first hematopoietic stem cell transplantation: A single center study.
Lu Y; Zhang JP; Zhao YL; Xiong M; Sun RJ; Cao XY; Wei ZJ; Zhou JR; Liu DY; Yang JF; Zhang X; Lu DP; Lu P
Front Immunol; 2022; 13():1066748. PubMed ID: 36685540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
